Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Immune Checkpoint Therapy
Treatment NA
Drugstatus NA
Drugbank ID NA
Checkpoints PD-1
Signature Type Gene
Signature JAK3
Official Symbol JAK3
Mode of action MU_R_GAIN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental patients
Description We tested the relationship between JAK3 germline mutations and mutations intwo DNA repair pathway genes on the panel ATM and MLH1,BRAF, and the JAK2p.V617F mutation; our analysis revealed near complete mutual exclusivity amongthese mutations , suggesting JAK3 germline mutation could be a novel, independent genetic marker for responses to anti-PD1 immunotherapy.
PMID 29082853
Title Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK4 with therapeutic implications